Clarithromycin-Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications

Isabel H Gonzalez-Bocco,Muneerah M Aleissa,Eric Zhou,Jennifer Manne-Goehler,Sophia Koo,Matthew P Cheng,Francisco M Marty

OPEN FORUM INFECTIOUS DISEASES（2022）

引用 0|浏览11

暂无评分

摘要

Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin's CYP induction. We found no differences in adverse events (10/13 vs 14/17; P = .73), drug intolerability (1/5 vs 4/11; P = 1), or 90-day mortality (0/13 vs 1/17; P = 1) in patients receiving clarithromycin vs azithromycin.

查看译文

关键词

clarithromycin, immunocompromised host, Mycobacterium avium complex, nontuberculous mycobacteria

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要